Onco therapeuticsPub Date : 2022-01-01DOI: 10.1615/oncotherap.v9.i2.50
Andrea Cedillo Ornelas, Sam Ferguson, Maya DePlaza, Tkai Adekunle, Riyaz Basha
{"title":"Anti-Cancer Pectins and Their Role in Colorectal Cancer Treatment.","authors":"Andrea Cedillo Ornelas, Sam Ferguson, Maya DePlaza, Tkai Adekunle, Riyaz Basha","doi":"10.1615/oncotherap.v9.i2.50","DOIUrl":"10.1615/oncotherap.v9.i2.50","url":null,"abstract":"<p><p>A class of plant polysaccharides, pectin is known to display several medicinal properties including in cancer. There is some evidence that pectin from some fruits can reduce the severity of colorectal cancer (CRC) due to its antiproliferative, anti-inflammatory, antimetastatic and pro-apoptotic properties. Pectin fermentation in the colon induces antiproliferative activity via butyrate. Research also showed that pectin acts as a potent inducer of programmed cell death and cell-cycle arrest, thereby selectively targeting cancer cells. Pectin can limit oxidative stress to maintain cellular homeostasis while increasing reactive oxygen species damage to activate cancer cell death. Pectin regulates various signaling cascades, e.g., signal transduction and transcriptional activator and mitogen-activated protein kinase signaling, that contribute to its anticancer activity. By curbing inflammation-activated signaling and bolstering immune-protective mechanisms pectin can eradicate CRC. Due to its chemical structure, pectin can also inhibit galectin-3 and suppress tumor growth and metastasis. Prior reports also suggested that pectin is beneficial to use alongside the CRC standard care. Pectin can increase sensitivity to conventional CRC drugs, alleviate unwanted side effects and reduce drug resistance. Although some preclinical studies are promising, early clinical trials are showing some evidence for pectin's efficacy in tumor growth inhibition and preventing metastasis in some cancers; however, the clinical use of pectin in CRC therapy is not yet well established. Further studies are needed to confirm the efficacy of pectin treatment as a valid clinical therapy for CRC in humans.</p>","PeriodicalId":74340,"journal":{"name":"Onco therapeutics","volume":"9 2","pages":"43-55"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259824/pdf/nihms-1906074.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9631252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Onco therapeuticsPub Date : 2022-01-01DOI: 10.1615/oncotherap.2022046215
Sagar Jangde, M. R. Purohit, Falguni Saraf, N. Merchant, Bhaskar Lvks
{"title":"Dietary Phytocompounds for Colon Cancer Therapy","authors":"Sagar Jangde, M. R. Purohit, Falguni Saraf, N. Merchant, Bhaskar Lvks","doi":"10.1615/oncotherap.2022046215","DOIUrl":"https://doi.org/10.1615/oncotherap.2022046215","url":null,"abstract":"","PeriodicalId":74340,"journal":{"name":"Onco therapeutics","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77560563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
